Výsledky vyhledávání

Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: A German claims data analysis

Autor: Thomas Wilke, Johannes Foersch, Nils Picker, Maximilian Gabler, Matthias Riedl, Jens Aberle, S Geier, Stephan Martin

Publikováno v: Diabetes research and clinical practice. 174

Background This study describes real-world treatment-related outcomes and healthcare costs of German type 2 diabetes mellitus (T2D) patients who initiated insulin therapy. Methods This retrospective analysis includes German claims data from 01/01/201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5069d92141d51b5c7b2810516d575b67
https://pubmed.ncbi.nlm.nih.gov/33737213

Zobrazit plný text záznamu

Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas

Autor: James Waddell, Dominic A. Solimando, Kyle E. Adkins

Publikováno v: Hospital Pharmacy. 50:194-198

Dr. Adkins is an oncology pharmacist, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Walter Reed National Military Medical Center, Bethesda, Maryland. At the time this manuscript was written, he was an Oncology Pharmacy Resident (PGY-2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d59fe984f36d992a3018d12bf7f7708b
https://doi.org/10.1310/hpj5003-194

Zobrazit plný text záznamu

A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center

Autor: Dnb, Mnams, Yatan Pal Singh Balhara

Publikováno v: Journal of Opioid Management. 10:200-206

Objective: The current study aimed at comparison of retention rates for daily dispensing (DD) and alternate-day dispensing (AD) regimens for buprenorphine over a 1-year period at a tertiary care treatment center for management of substance use disord

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea14f01e5e4b3b0a7ffe47ff7fbf013
https://doi.org/10.5055/jom.2014.0208

Zobrazit plný text záznamu

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity

Autor: Chantal Burghoorn-Maas, Martine L.M. Lamfers, Suzan D. Pas, Reno Debets, Sieger Leenstra, Anne Kleijn, Wouter B.L. van den Bossche, Clemens M F Dirven, Jeroen de Vrij, Zineb Belcaid, Jenneke Kloezeman, Erik S. Haefner

Publikováno v: Molecular Therapy-Oncolytics, 5, 11-19. Cell Press
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 11-19 (2017)

The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b810104e6374f4d57ea81e8f5908083
https://pure.eur.nl/en/publications/4533f29a-5405-46a1-a03e-34fe09af80cd

Zobrazit plný text záznamu

Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

Autor: Min-Han Tan, Han Kiat Ho, Noan Minh Chau, Yi Ling Teo, Xiu Ping Chue, Alexandre Chan, Hwee Lin Wee, Ravindran Kanesvaran

Publikováno v: Targeted oncology. 10(3)

An attenuated dosing (AD) regimen of 37.5 mg daily in repeated 4 week on, 2 week off cycles has been proposed to ameliorate frequent dose modifications caused by the toxicity observed with the approved dosing regimen of sunitinib for metastatic renal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1be6e3a6232f27e72fc51d4b48f027a4
https://pubmed.ncbi.nlm.nih.gov/25502986

Zobrazit plný text záznamu

Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib

Autor: Hwee Lin Wee, Yi Ling Teo, Ravindran Kanesvaran, Xiu Ping Chue, Noan-Minh Chau, Han Kiat Ho, Min-Han Tan, Alexandre Chan

Publikováno v: Journal of Clinical Oncology. 32:439-439

439 Background: An alternative dosing (AD) regimen of 37.5mg daily in repeated 4-weeks on, 2-weeks off cycle has been proposed to ameliorate frequent dose modifications due to toxicities as observed with the approved dosing regimen of sunitinib for m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b7757cc673492ccf25a0c36f583d662
https://doi.org/10.1200/jco.2014.32.4_suppl.439

Zobrazit plný text záznamu

Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib

Autor: Xiu Ping Chue, Hwee Lin Wee, Min-Han Tan, Noan-Minh Chau, Han Kiat Ho, Alexandre Chan, Yi Ling Teo, Ravindran Kanesvaran

Publikováno v: Journal of Clinical Oncology. 31:e13582-e13582

e13582 Background: An AD regimen of 37.5mg daily in repeated 4-weeks on, 2-weeks off cycle has been proposed to ameliorate frequent dose modifications due to toxicities as observed with the approved dosing regimen of sunitinib for mRCC. This study ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6d99a44a108e7aace1fa9f9a164a281
https://doi.org/10.1200/jco.2013.31.15_suppl.e13582

Zobrazit plný text záznamu

Which is Your Choice? Neoadjuvant Adriamycin and Doxetaxel (AD) Versus Adriamycin, Cyclophosphamide and Paclitaxel (AC-T) in Locally Advanced Breast Cancer

Autor: Hye-Ryun Lee, J. Choi, Suk-Hwan Kang, Mi Sun Ahn, Kwangsoo Kim

Publikováno v: Annals of Oncology. 23:xi127

Background It is well known that neoadjuvnat chemotherapy is acceptable for women with locally advanced breast cancer. However, it is not achieving consensus that what kind of regimen is most effective and tolerable, although lots of regimens and dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebc22b18c091362a5edf6821591eb0cd
https://doi.org/10.1016/s0923-7534(20)32362-0

Zobrazit plný text záznamu

3P Which is Your Choice? Neoadjuvant Doxorubicin and Doxetaxel (Ad) Versus Doxorubicin, Cyclophosphamide and Paclitaxel (Act) in Locally Advanced Breast Cancer

Autor: K.S. Kim

Publikováno v: Annals of Oncology. 23:ii15

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da3e0d1e94cea8cdeca4414e281328f6
https://doi.org/10.1016/s0923-7534(19)65656-5

Zobrazit plný text záznamu

PD06-05: Primary and Secondary Pegfilgrastim Utilization in Adjuvant Chemotherapy for Breast Cancer in the Community

Autor: M.A. Neubauer, R. W. Anderson, Leslie T. Busby, Janet L. Espirito, Roy A. Beveridge, Barry Don Brooks, Debra A. Patt, Brian Turnwald, John Russell Hoverman, Michael Kolodziej

Publikováno v: Cancer Research. 71:PD06-05

Background Various factors are taken into consideration in the selection of adjuvant breast cancer (BC) chemotherapy (CT) regimens for patients. Choice of CT, schedule, duration, and supportive care affects costs and toxicity. Understanding clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4089c4cccfa61ed68d0c4c4a0995ca30
https://doi.org/10.1158/0008-5472.sabcs11-pd06-05

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání